Rational Design of TDP-43 Derived α-Helical Peptide Inhibitors: An In Silico Strategy to Prevent TDP-43 Aggregation...

Area of Science:

• Neuroscience
• Biochemistry
• Computational Biology

Background:

• TDP-43 protein aggregation is central to neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
• Pathological TDP-43 disrupts neuronal function through mislocalization and aggregation, often involving the destabilization of an alpha-helical segment in its C-terminal region.
• Amyloid-like filament formation in TDP-43 pathology is a key target for therapeutic intervention.

Purpose of the Study:

• To computationally design and evaluate peptide-based therapeutics targeting pathological TDP-43 amyloid-like filaments.
• To identify peptides that can bind to TDP-43 filaments and prevent the conversion to beta-sheet structures, thereby inhibiting aggregation.
• To explore the potential of stabilizing the alpha-helical domain of TDP-43 as a therapeutic strategy.

Main Methods:

• Utilized a range of in silico techniques including biophysical property prediction, secondary structure prediction, molecular docking, 3D structure prediction, and molecular dynamics simulations.
• Assessed peptide structure, stability, and binding affinity to pathological TDP-43 amyloid-like filaments.
• Performed molecular dynamics simulations over 300 ns to evaluate structural and thermodynamic stability.

Main Results:

• Identified promising peptides with stable alpha-helical structures and increased intramolecular hydrogen bonds.
• Demonstrated high binding affinities of designed peptides for pathological TDP-43 amyloid-like filaments.
• Molecular dynamics simulations confirmed the structural and thermodynamic stability of lead candidate peptides.

Conclusions:

• Alpha-helical propensity peptides represent potential lead molecules for novel therapeutics against TDP-43 aggregation.
• A structure-based computational approach enables the rational design of peptide inhibitors for neurodegenerative diseases.
• These findings open new avenues for developing interventions for ALS, FTD, and related disorders, with promising candidates undergoing further experimental validation.